Is Agenus Inc (AGEN) overvalued? · P/E 1.6, rev $103.5M
Agenus Inc (AGEN) is a biotechnology company listed on US.
This page asks whether Agenus Inc (AGEN) looks expensive on cached numbers — not a short thesis.
Latest reported AGEN revenue for 2024-12-31 was $103.5M. Net income was -$232.3M. Revenue was down 33.8% from 2023-12-31 to 2024-12-31. AGEN currently screens at market cap $134.5M and trailing P/E 1.6.
AGEN currently screens at market cap $134.5M and trailing P/E 1.6. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AGEN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AGEN stock page for the full model, not this heading.
Not investment advice.